Syros Pharmaceuticals - SYRS Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $30.00 to $100.00. On average, they predict the company's stock price to reach $72.50 in the next twelve months. This suggests a possible upside of 991.9% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.

Syros Pharmaceuticals' stock was trading at $32.60 on January 1st, 2022. Since then, SYRS stock has decreased by 79.6% and is now trading at $6.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our SYRS earnings forecast.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($5.40) EPS for the quarter, missing the consensus estimate of ($4.20) by $1.20. The company earned $6.28 million during the quarter, compared to the consensus estimate of $4.68 million. Syros Pharmaceuticals had a negative net margin of 433.67% and a negative trailing twelve-month return on equity of 157.22%.

Syros Pharmaceuticals shares reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYRS stock can currently be purchased for approximately $6.64.

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $41.83 million and generates $23.49 million in revenue each year. The company earns $-86,560,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

The company employs 124 workers across the globe.

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.